company background image
VBLT logo

Vascular Biogenics NasdaqCM:VBLT 株式レポート

最終価格

US$0.16

時価総額

US$12.1m

7D

-34.5%

1Y

9.2%

更新

17 Oct, 2023

データ

会社財務

Vascular Biogenics Ltd.

NasdaqCM:VBLT 株式レポート

時価総額:US$12.1m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

VBLT 株式概要

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States.

VBLT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Vascular Biogenics Ltd. 競合他社

価格と性能

Summary of all time highs, changes and price drops for Vascular Biogenics
Historical stock prices
Current Share PriceUS$0.16
52 Week HighUS$0.32
52 Week LowUS$0.10
Beta0.71
1 Month Change-33.33%
3 Month Change-45.07%
1 Year Change9.17%
3 Year Change-86.55%
5 Year Change-88.53%
Change since IPO-97.33%

最新ニュース

Recent updates

VBL Therapeutics receives non-compliance letter from Nasdaq

Sep 01

VBL Therapeutics GAAP EPS of -$0.12

Aug 15

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Jul 19

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Sep 03

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17
How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

Jan 28
How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

VBL Therapeutics expands the ovarian cancer trial in Europe

Dec 29

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24
Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 19
Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

VBL Therapeutics EPS beats by $0.01, misses on revenue

Nov 16

株主還元

VBLTUS BiotechsUS 市場
7D-34.5%-2.0%1.6%
1Y9.2%5.4%21.5%

業界別リターン: VBLT過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: VBLTは、過去 1 年間で21.8 % のリターンを上げたUS市場を下回りました。

価格変動

Is VBLT's price volatile compared to industry and market?
VBLT volatility
VBLT Average Weekly Movement13.5%
Biotechs Industry Average Movement10.4%
Market Average Movement5.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

安定した株価: VBLTの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: VBLTの weekly volatility ( 14% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
20007Dror Haratswww.vblrx.com

Vascular Biogenics Ltd. 基礎のまとめ

Vascular Biogenics の収益と売上を時価総額と比較するとどうか。
VBLT 基礎統計学
時価総額US$12.11m
収益(TTM)-US$15.95m
売上高(TTM)US$481.00k

25.2x

P/Sレシオ

-0.8x

PER(株価収益率

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
VBLT 損益計算書(TTM)
収益US$481.00k
売上原価US$17.00k
売上総利益US$464.00k
その他の費用US$16.42m
収益-US$15.95m

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益(EPS)-0.21
グロス・マージン96.47%
純利益率-3,317.05%
有利子負債/自己資本比率0%

VBLT の長期的なパフォーマンスは?

過去の実績と比較を見る